88
Views
7
CrossRef citations to date
0
Altmetric
Clinical Features

Overcoming Therapeutic Inertia in Patients with Hypertension

, MD
Pages 118-124 | Published online: 13 Mar 2015

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Articles from other publishers (6)

Domingo Orozco-Beltran, Jose A. Quesada, Vicente Bertomeu-Gonzalez, Jose M. Lobos-Bejarano, Jorge Navarro-Perez, Vicente F. Gil-Guillen, Luis Garcia Ortiz, Adriana Lopez-Pineda, Angel Castellanos-Rodriguez, Angela Lopez-Domenech, Antonio Francisco J. Cardona-Llorens & Concepcion Carratala-Munuera. (2020) A new risk score to assess atrial fibrillation risk in hypertensive patients (ESCARVAL-RISK Project. Scientific Reports 10:1.
Crossref
Carlos Escobar, Vivencio Barrios, F. Javier Alonso-Moreno, Miguel Angel Prieto, Francisco Valls, Alberto Calderon & Jose Luis Llisterri. (2014) Evolution of therapy inertia in primary care setting in Spain during 2002–2010. Journal of Hypertension 32:5, pages 1138-1145.
Crossref
Benjamin J. Epstein, Niren K. Shah & Nancy L. Borja-Hart. (2013) Management of hypertension with fixed-dose triple-combination treatments. Therapeutic Advances in Cardiovascular Disease 7:5, pages 246-259.
Crossref
Shawna Nesbitt, Ali Shojaee & Jen-Fue Maa. (2013) Efficacy/Safety of a Fixed-Dose Amlodipine/Olmesartan Medoxomil-Based Treatment Regimen in Hypertensive Blacks and Non-Blacks With Uncontrolled BP on Prior Antihypertensive Monotherapy. The Journal of Clinical Hypertension 15:4, pages 247-253.
Crossref
Pierre-François Plouin & Nicolas Postel-vinay. (2012) Traitement de l’hypertension artérielle : présent et perspectives. Bulletin de l'Académie Nationale de Médecine 196:2, pages 515-520.
Crossref
Annet Kirabo & Peter P. Sayeski. (2010) Jak2 Tyrosine Kinase: A Potential Therapeutic Target for AT1 Receptor Mediated Cardiovascular Disease. Pharmaceuticals 3:11, pages 3478-3493.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.